Bristol-Myers Squibb Company (‘Bristol Myers Squibb’) engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.
The company’s principal…
Analysis
Hidden champion
Bristol-Myers Squibb Company fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns.
On valuation, the picture is attractive. The owner-earnings multiple stands at 12.1×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -0% a year, against analyst forecasts of -2%. The price, in other words, assumes less than the experts do.
Growth is tepid; the safety picture is stretched. The company scores 14/20 on our value-creation score: strong value creator.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202355
56
2023202420252026
All-time high
79
May 2025
All-time low
16
Feb 2024
Average rank
50
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
71
43
37
40
Price/Earnings
27
83
91
96
Price/Book
42
23
19
35
Dividend Yield
97
98
98
98
Value (overall)
91
92
89
94
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.